Analyzing R&D Budgets: BioMarin Pharmaceutical Inc. vs Perrigo Company plc

BioMarin's R&D surge vs. Perrigo's strategic shift

__timestampBioMarin Pharmaceutical Inc.Perrigo Company plc
Wednesday, January 1, 2014461543000152500000
Thursday, January 1, 2015634806000187800000
Friday, January 1, 2016661905000184000000
Sunday, January 1, 2017610753000167700000
Monday, January 1, 2018696328000218600000
Tuesday, January 1, 2019715007000187400000
Wednesday, January 1, 2020628116000177700000
Friday, January 1, 2021628793000122000000
Saturday, January 1, 2022649606000123100000
Sunday, January 1, 2023746773000122500000
Monday, January 1, 2024747184000
Loading chart...

Unleashing the power of data

A Decade of Innovation: BioMarin vs. Perrigo

In the ever-evolving pharmaceutical landscape, research and development (R&D) are the lifeblood of innovation. Over the past decade, BioMarin Pharmaceutical Inc. and Perrigo Company plc have demonstrated contrasting approaches to R&D investment. BioMarin, renowned for its focus on rare genetic diseases, has consistently increased its R&D budget, peaking at a 62% rise from 2014 to 2023. This commitment underscores BioMarin's dedication to pioneering treatments. In contrast, Perrigo, a leader in over-the-counter health products, has seen a 20% decline in R&D spending over the same period. This shift reflects Perrigo's strategic pivot towards optimizing existing product lines rather than expanding its research frontier. As the pharmaceutical industry faces mounting pressure to innovate, these trends highlight the diverse strategies companies employ to balance growth and sustainability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025